JPMorgan Adds New Stocks to Its October Favorites List

BeInCrypto2026/10/05 06:51

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

JPMorgan has added new names to its October list of favorite stock ideas, including American Express, Liberty Energy and Thermo Fisher Scientific. Each carries an overweight rating from the banks analysts. The refresh lands after a split September on Wall Street. The Dow Jones Industrial Average lost 4.3%, the SP 500 slipped 0.5%, and the Nasdaq Composite gained 1.9%. October Arrives With a Friendlier Track Record September has long been the weakest month for US stocks, as BeInCrypto noted at the start of the month. Barchart data show SPDR SP 500 ETF total returns averaging 2.27% in October since 2010. That ranks third among all 12 months, behind November at 3.09% and July at 2.79%. September averaged a 0.48% loss over the same stretch. Meanwhile, the third quarter closed with the Dow down 3%. The SP 500 and the Nasdaq each advanced at least 2% over the period. Why Do JPMorgans October Stock Picks Include a Falling Card Issuer? JPMorgan sorts its overweight-rated stocks into growth, income, value, and short strategies. American Express is one of five new names and sits in the value group. The stock closed at $302.78 on October 2, down 18.16% year to date, Google Finance data shows. American Express Stock Performance. Source: Google Finance Doubts over consumer spending and volatile credit rates have weighed on the shares. Analyst Richard Shane still backs the stock. AXP remains a core holding for investors looking for industry leading high returns and disciplined return of capital (dividend plus repurchases 3% of shares year after year), he stated. Can AI Demand Keep Carrying Stocks That Already Rallied? Liberty Energy, a growth pick, has climbed 52% over the past year. Its Liberty Power Innovations unit builds on-site generation for large power users. In January, the unit agreed to supply up to 1 gigawatt of power for Vantage Data Centers within 5 years. Analyst Arun Jayaram expects tight power supply to keep that demand going. We are seeing a reinforced structurally tight behind-the-meter power backdrop tied to data center load growth, with a power deficit expected to persist into 2030, which supports a multi-year demand runway for distributed generation providers, Jayaram said in a note to clients. Thermo Fisher, the second named growth pick, closed at $654.80 on October 2, up 13% year to date. Its shares have gained more than 25% over the past 3 months. In September, Mayo Clinic launched Precure, an early disease detection venture, with Thermo Fisher as founding partner. Analyst Casey Woodring sees further gains from wider AI adoption and US biopharma reshoring.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Search string for querying individual stock trends in the workspace: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Brief" newsletter: https://refini.tv/3dKUyB8 Reuters, October 5 - On Monday, U.S. stock index futures edged lower as tech stocks retreated after reaching record highs. As Treasury yields and oil prices remain elevated, investors are seeking new clues about the direction of monetary policy. .N ** RXO RXO.N: Market focus — RXO shares rose following C.H. Robinson's announcement of a 5.8 billions USD acquisition plan nL6N45R0N4 ** Harley-Davidson HOG.N: Market focus — Citi upgraded Harley-Davidson to "Buy," shares climbed nL6N45R0M3 ** GEO Group GEO.N: Spotlight — GEO gained as it sold ICE facilities for 950 millions USD and expanded its stock buyback nL6N45R0MR ** Vistra VST.N: Spotlight — Vistra rallied as it was reportedly set to receive a 4.2 billions USD U.S. nuclear loan nL4N45R0L8 ** Vaxcyte PCVX.O: Spotlight — Vaxcyte surged after positive late-stage clinical trial data for its pneumococcal vaccine nL4N45R0K0 ** Estée Lauder EL.N: Spotlight — Barclays upgraded Estée Lauder to "Overweight," shares advanced nL6N45R0HX ** PTC PTC.O: Spotlight — Schneider Electric agreed to acquire PTC for 22.6 billions USD, shares jumped nL6N45R0HV (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automatic translation may contain errors or fail to convey the required context, Reuters does not guarantee the accuracy of automatically translated texts and provides them solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from the use of automated translation features.)

路透社•2026/10/05 12:06

An unidentified treasury has suffered a $60,000 multi-signature vulnerability attack, putting $317,000 at risk.

Mpost•2026/10/05 12:01

BUZZ-Alector stock surges after agreement with Genentech on an experimental Parkinson's disease drug

October 5 - The stock price of pharmaceutical company Alector (ALEC.O) surged by 44.20% in pre-market trading, reaching $2.61. The company has entered into a global licensing agreement with Genentech for AL050, an experimental drug developed by ALEC for the treatment of Parkinson's disease. ALEC has granted Genentech the exclusive worldwide rights to develop and commercialize AL050. According to ALEC, the agreement will bring an upfront payment of $100 million and may result in milestone payments of up to $1.17 billion by 2029. The company retains ownership of its ABC technology platform for developing therapies for neurodegenerative diseases, as well as all rights to use the platform in its research and development pipeline. As of the close of the previous trading day, ALEC's stock price had risen by 16.03%. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Due to possible errors in automation or lack of context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation.)

路透社•2026/10/05 11:54

How Far Can 12 Straight Wins Take a Trader Who Is Still Down $22.8 Million?

BeInCrypto•2026/10/05 11:51